Relievant Medsystems
- Industry
- Medical Devices & Instruments
- Founded Year
- 2006
- Headquarters
- 7201 Metro Blvd #300, Edina, MN 55439
- Employee Count
- 220
Key People
- Tyler Binney - President and CEO
- Ray Baker - COO and CMO
- Chris Geyen - Chief Financial Officer
- Brian Donovan - Vice President, Research & Development and Operations
- Patrick Lyon - Vice President, Marketing
- Diane M. Sahr - VP Clinical Affairs
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with significant backgrounds in the medical device industry.
The leadership team includes individuals with substantial experience in the medical device sector, enhancing the company's strategic direction and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: The Intracept Procedure addresses a significant unmet need in treating chronic low back pain.
Chronic low back pain affects millions, and existing treatments often fall short. The Intracept Procedure provides a minimally invasive option with demonstrated efficacy, fulfilling a critical clinical need.
- Competition
-
Aspect: First mover
Summary: Relievant Medsystems is a pioneer in basivertebral nerve ablation for chronic low back pain.
As the first company to offer a FDA-cleared basivertebral nerve ablation system, Relievant has established a strong market position with limited direct competition.
- Technical Challenge
-
Aspect: Predictable
Summary: The Intracept Procedure is a minimally invasive technique with a well-understood mechanism of action.
The technology involves targeted energy delivery to the basivertebral nerve, a process that is technically feasible and has been successfully implemented in clinical settings.
- Patent
-
Aspect: Very Strong
Summary: Relievant holds robust patents protecting its Intracept technology.
The company's patents cover key aspects of the Intracept Procedure, providing a significant barrier to entry for potential competitors and safeguarding its innovative technology.
- Financing
-
Aspect: Strategics
Summary: Acquired by Boston Scientific for $850 million, indicating strong financial backing.
The acquisition by a major medical device company not only validates Relievant's technology but also ensures access to extensive resources, distribution networks, and market expertise.
- Regulatory
-
Aspect: 510k/PMA + Reimbursement
Summary: The Intracept System is FDA-cleared with expanding insurance coverage.
FDA clearance and increasing coverage from major insurers enhance the procedure's accessibility and adoption among healthcare providers and patients.
Opportunity Rollup
- Odds of Success
- 4.9
- Peak Market Share
- 7.15
- Segment CAGR
- 9.5%
- Market Segment
- Medical Devices & Instruments
- Market Sub Segment
- Spinal Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.36 |
| 2 | 1.07 |
| 3 | 2.50 |
| 4 | 5.00 |
| 5 | 7.15 |
Key Takeaway
Relievant Medsystems, with its innovative Intracept Procedure and strong backing from Boston Scientific, is well-positioned to address the significant unmet need in chronic low back pain treatment, offering a promising investment opportunity in the growing spinal devices market.